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Oxidative stress in the brain plays an important role in the pathogenesis of dementia. The rhizome of temulawak
(Curcuma xanthorrhiza Roxb.) contains curcumin and xanthorrhizol which possess antioxidant activity and thus
has the potential to deter oxidative stress. This study aims to identify the effect of the ethanol extract of a
temulawak rhizome on the malondialdehyde (MDA) levels and glutathione peroxides (GPx) activity in the brains
of trimethyltin (TMT) induced dementia model rats. The study employed 30 adult male Sprague Dawley rats
divided into six groups, each consisting of ﬁve rats. The normal group was given a CMC-Na 1% solution
orally, the TMT group also received a CMC-Na 1% solution orally, while the treatment groups were orally given
temulawak rhizome extract (TRE) with doses of 50 (E50), 100 (E100) and 150 mg/kg bw (E150), and 200 mg/kg
bw of citicoline (Cit200), respectively. Before treatment, all groups, except the normal group, were injected with
single doses of 8 mg/kg bw of TMT intraperitoneally. The treatment was administered for 21 days. On the 29th
day the rats were sacriﬁced, their brains were retrieved and had their hemispherium cerebri separated for the
measurement of the MDA levels and GPx activity in its homogenate. Data of the MDA levels and GPx activity
were statistically analyzed with a one-way ANOVA test followed by a posthoc LSD test. Results showed that
TMT injection could raise the MDA levels and lower GPx activity (p < 005). The administration of TRE with a
dose of 50 mg/kg bw was able to inhibit increase in MDA levels and augment GPx activity in the brain but had
signiﬁcant difference from the normal group (p < 005). Meanwhile, the administration of 100 and 150 mg/kg
bw doses of TRE could prevent rise in MDA levels and enhance GPx activity of the brain (p < 005) with no
meaningful difference from the normal group and the group given citicoline (p > 005). It can be concluded from
these results that TRE in doses of 100 and 150 mg/kg bw can avert oxidative stress in TMT induced dementia
model rats.
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1. INTRODUCTION
Dementia is a term used to describe a collection of memory
disorder symptoms such as forgetfulness, disorientation, commu-
nication difﬁculties, and the declining capability to analyze and
make decisions.1 Oxidative stress is the imbalance between free
radicals and antioxidants, a signiﬁcant pathogenesis in the devel-
opment of dementia.2 Increasing oxidative stress prompts brain
neuron degeneration which may cause dementia.34 Brain cells
are highly vulnerable to oxidative damage as the brain is an organ
which greatly requires oxygen. The levels of unsaturated fatty
acids in the brain are high, but its antioxidant defense system
is relatively weaker than in other organs.5 Oxidative damage to
lipids and proteins may lead to functional and structural disor-
ders of cell membranes, enzyme inactivity, and eventually cell
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death.6 Oxidative damage to lipids produces malondialdehyde
(MDA), 4-hydroxy-2, 3-nonenal (HNE), acrolein, etc., Endoge-
nous antioxidants in the body such as glutathione peroxidase
(GPx) contribute in preventing such oxidative damage.7
Temulawak (Curcuma xanthorrhiza Roxb.) is a medicinal herb
widely used as raw ingredient in the jamu (traditional medicine)
and pharmaceutical industries. Several conducted studies have
shown that temulawak contains curcumin and xanthorrhizol com-
pounds which are recognized as potential antioxidants.89 Antiox-
idant activity has proved its function in abating oxidative damage
and memory deﬁcit related to neuron degenerative disorders
including dementia.10 The purpose of this research is to iden-
tify the effect of temulawak rhizome extract on the levels of
malondialdehyde (MDA) and the activity of glutathione peroxi-
dase (GPx) in the brains of trimethyltin (TMT) induced dementia
model rats. It is expected that this study will serve as basis for
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the development of natural ingredients, particularly temulawak,
as a dementia deterrent.
2. EXPERIMENTAL DETAILS
2.1. Animals
The animals employed were Sprague Dawley male rats, weigh-
ing 150–250 g and aged 2.5 to 3 months, obtained from the
Integrated Research and Testing Laboratory (LPPT) of Universi-
tas Gadjah Mada (UGM), Yogyakarta, Indonesia. The test ani-
mals were treated in a laboratory condition of 25 to 26 C
temperatures, 60–65% humidity with a light exposure cycle
of 12 hours of bright and dark, and received feed and water
ad libitum.
2.2. Materials
Dried temulawak rhizome simplicia was procured from CV.
Merapi Farma, Yogyakarta. Chemicals comprising silica gel 60
F254, chloroform, methanol, ethanol 96%, NaCl 0.9%, CMC-Na
1%, and TMT were bought from Sigma-Aldrich. Citicoline was
purchased from PT. Bernofarm, while other chemicals namely
KCl, sodium dodecyl sulfate, acetic acid solution, n-butane, pyri-
dine, NaOH, thiobarbituric acid, and 1,1,3,3-tetraethoxypropane
(TEP) were bought from the Food and Nutrition Laboratory, Uni-
versitas Gadjah Mada, Indonesia.
2.3. Experimental Procedures
2.3.1. Extraction and Standardization of
Temulawak Extract
Temulawak rhizome extract was acquired by applying a macer-
ation method with ethanol 96%. Identiﬁcation of the curcumin
compound in the extract was done by thin layer chromatography
(TLC) using the mobile phase of chloroform and methanol (with
a ratio of 9:1) and the stationary phase of silica gel 60 F254.
Afterwards, the curcumin levels in the extract were determined
using a densitometer with a wavelength of 426 nm. In addition,
examination was also performed on the non-speciﬁc parameters
of the extract, including the water levels, the total ash levels and
the acid-insoluble ash levels.
2.3.2. Experimental Design
All stages in this study have been approved by the Ethics Com-
mission for Preclinical Research at LPPT UGM with article num-
ber 147/KEC-LPPT/V/2014.
As many as 30 rats that had been adapted for a week were
split into six treatment groups, each consisting of ﬁve rats. The
normal group orally received a CMC-Na 1% solution, the TMT
group was also given a CMC-Na 1% solution orally, and the
extract group was orally given the temulawak rhizome extract,
each with a dose of 50 mg/kg bw (E50), 100 mg/kg bw (E100),
and 150 mg/kg bw (E150), respectively. The next group received
200 mg/kg bw of citicoline orally. Prior to treatment, all groups
were intraperitoneally injected with 8 mg/kg bw of TMT with
the exception of the normal group. Treatment was administered
for 21 days and on the 29th day the rats were sacriﬁced by
means of CO2 gas. The brain tissue was then retrieved and the
hemispherium cerebri separated for the measurement of the MDA
levels and GPx activity in the brain.
2.3.3. Brain MDA Level Measurement
The brain MDA level measurement was conducted per procedure
utilized by Colado et al.11 The MDA levels were gauged based on
TBA reaction using a spectrophotometer at 532 nm wavelength
with tetra ethoxy propane (TEP) as standard solution. The MDA
levels were presented in nmol/mg tissue units.
2.3.4. Brain GPx Enzyme Activity Measurement
Brain GPx activity was measured following a method by
Wendel.12 GPx reduced cumene hydro peroxide which oxidized
GSH into GSSG. The GSSG was then reduced into GSH by
glutathione reductase with NADPH. Decline in NADPH levels
directly proportional to GPx activity was determined by spec-
trophotometer at 340 nm wavelength. GPx activity was presented
in mU/mg protein units.
2.3.5. Protein Determination
Protein levels were gauged with Lowry’s method13 using bovine
serum albumin (BSA) (1 mg/mL) as standard.
2.3.6. Data Analysis
Data of MDA levels and GPx activity were statistically analyzed
with a one-way ANOVA test followed by a post hoc LSD test.
Signiﬁcance of results was established if p < 005.
3. RESULTS AND DISCUSSION
3.1. Temulawak Rhizome Extract
The curcumin content of the temulawak rhizome extract was
identiﬁed by thin layer chromatography. The chromatogram pro-
ﬁle is presented in Figure 1.
Figure 1 indicates that temulawak rhizome extract contains
curcumin. The subsequent results of temulawak rhizome extract
standardization conducted in accordance with the Indonesian
Herbal Pharmacopeia can be seen in Table I.
Fig. 1. TLC proﬁle of standard curcumin and temulawak rhizome extract.
Legend: spot 1 (Rf 0.78) = curcumin; spot 2 (Rf 0.58) = desmethoxy cur-
cumin; spot 3 (Rf 0.49) = bisdemethoxy curcumin; spot a–f = standard cur-
cumin; and spot g–i= temulawak rhizome extract.
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Table I. Temulawak rhizome extracts standardization results.
Level terms as per the Indonesian Obtained
Testing herbal pharmacopeia (%) levels (%)
Curcumin levels ≥14.20 1759±048
Water levels <10 836±027
Total ash levels ≤7.8 515±030
Acid-insoluble ≤1.6 046±003
ash levels
The standardization results in Table I show that the temulawak
ethanol extract used in this study fulﬁls the quality standards of
the Indonesian Herbal Pharmacopeia.
3.2. Brain MDA Level and GPx Activity
The MDA level and GPx activity of the rats’ brains are displayed
in Figures 2 and 3.
Statistical analysis by one way ANOVA and posthoc LSD test
revealed that TMT 8 mg/kg bw injections could raise MDA lev-
els and lower GPx activities in the rats’ brains signiﬁcantly when
compared with the normal group (p < 005). MDA is a com-
pound resulting from a non-enzymatic process and is the end
product of lipid per oxidation. MDA measurement can become
an indicator of oxidative damage affected by the presence of
lipid peroxides due to an increase of free radicals.14 Exposure
to TMT has been known to intensify the formation of reactive
oxygen species (ROS) and reactive nitrogen species (RNS) of
free radicals15 and lessen the activity of endogenous antioxidants,
including GPx, thus prompting oxidative stress conditions Aug-
mentation of ROS and RNS will enhance glutathione oxidation,
lipid per oxidation and oxidation of protein.1516 TMT has also
been proven to bring about selective degeneration in the central
nervous system leading to selective neuronal death, particularly
at the hippocampus.1718 The hippocampus is the part of the brain
involved in memory processing TMT intoxication in test animals
has been largely used to generate models of neurodegenerative
disorders such as Alzheimer dementia.19–21
The administration of temulawak rhizome extract in doses of
50, 100, and 150 mg/kg bw was able to deter rises of MDA levels
and GPx activity in the brain. More speciﬁcally, the administra-
tion of temulawak rhizome extract in doses of 100 and 150 mg/kg
bw could preclude increases in cerebral MDA and GPx activity
with no meaningful difference from the normal group (p > 005).
Certain studies have pointed out that the main active components
of temulawak are curcuminoids and xanthorrhizol. The primary
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Fig. 2. Levels of malondialdehyde (MDA) in all treatment groups of TMT
induced dementia model rats. Legend: ∗p < 005 signiﬁcantly different from
TMT group, #p < 005 signiﬁcantly different from normal group.
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Fig. 3. Brain glutathione peroxidase (GPx) activities in all treatment groups
of TMT induced dementia model rats. Legend: ∗p<005 signiﬁcantly different
from TMT group, #p < 005 signiﬁcantly different from normal group.
component of curcuminoids, curcumin has protective effects
onlipid peroxides and hence decreases MDA levels.2223 Cur-
cumin possesses the activity of a strong antioxidant which can
inhibit the growth and spread of free radicals, consequently curb-
ing the progression of neuron injury in Alzheimer dementia.2425
Curcumin can also increase glutathione peroxides (GPx) enzymes
because it is composed of phenolic hydroxyl groups which
are able to bind free radicals especially hydroxyl ones.26 With
the development of GPx enzymes, hydro peroxides are reduced
into water and glutathione is reduced as well, to the extent
that the growth of highly reactive hydroxyl radicals can be
avoided.27 Preclinic test results also show that xanthorrhizol con-
tained in temulawak exhibits potential neuro protective effects
and strong antioxidant activity by restraining lipid peroxidation
in the homogenate of a murine brain injected with glutamate.8
In this study the administration of 200 mg/kg bw of citicol-
ine divulged the ability to suppress increase in MDA levels and
enhance brain glutathione peroxides activity with no meaning-
ful difference from the normal group. Citicoline has been proven
as a neuroprotector that can prevent lipid peroxidation in nerve
cells and stimulate glutathione synthesis.28 The development of
glutathione as the enzyme substrate of glutathione peroxides
improves the activity of glutathione peroxides enzymes, which
act as antioxidants in the body, and decrease MDA levels.
4. CONCLUSION
It can be concluded from the research ﬁndings that temulawak
rhizome extract at doses of 100 and 150 mg/kg bw can stiﬂe
escalations in MDA levels and GPx activities in the brain of a
TMT induced dementia model rat. Other biochemical parameter
measurements are required in future studies in order to identify
the mechanism of temulawak extract in preventing dementia.
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